FAQ
|
Fact Sheet
|
Media Page
Blog
About Us
history
management
our team
awards
community service
in the media
Independent Research
research principles
executive informational overviews®
quarterly updates
distribution
Research Library
Contact Us
offices
careers
Subscribe by Email
Your email:
Most Popular Posts
NEW REPORT on PhotoMedex (PHMD): Marketer of no!no! Hair and more
APDN’s Anti-Counterfeiting Technology Addresses New Federal Legislation
Authentidate Holding Corp. (ADAT) Second Quarter FY 2012 Update
Jeff Kraws Weighs In on Supreme Court Victory for Generic Drug Makers
APDN's Revenues Rise 63% in the First Quarter FY 2012
New treatment for spine injuries could reverse paralysis: InVivo poised to enter clinical trials
Independent Equity Research Report on LRAD Corp. (LRAD-NASDAQ)
Neonode (NEON-OTC.BB) is Changing Your Touchscreen
Investor Highlights for PhotoMedex, Inc. (PHMD) (Week of 4/23-4/27)
InVivo Therapeutics (NVIV) Adds Senior Leadership in Preparation for Human Clinical Trial
Posts by Month
2012
May
April
March
February
January
2011
December
November
October
August
July
June
May
April
March
February
January
2010
December
November
October
Follow Crystal Research
Browse by Tag
A. Schulman (2)
AA amyloidosis (1)
ABKI (2)
Acoustic Hailing Devices (1)
ACT Biotech (1)
Advaxis (3)
Alain Cayer (1)
Albany NanoTech Complex (1)
anti-counterfeit (1)
APDN (3)
Applied DNA (5)
Applied DNA Sciences (2)
Aspen Aerogels (1)
Authentidate (3)
BASFY (2)
Bellus Health (1)
Bioniche (4)
biopharmaceuticals (2)
biotech (1)
Biotech Showcase (1)
BLU (1)
breast cancer (1)
Bridgelux (1)
built environment (3)
Calera Corp (1)
CalStar Products (1)
Cameco Corp (1)
cancer vaccine (1)
Caraco (1)
CBT (2)
CCC (2)
CEL-SCI (5)
cheating (1)
Cheever (1)
clean technology metals (1)
CNSE (1)
College of Nanoscale Science and Engineering (1)
computer chip (1)
CorMedix (3)
counterfeit (1)
Craig Dionne (1)
Crystal Research (10)
Crystal Research Associates (8)
CUR (1)
digitalDNA™ (1)
Document Capture Technologies (1)
Executive Informational Overview (6)
ExpressMD (1)
finance (3)
FOX40 (1)
Frank Reynolds (3)
Frederic Gauthier (1)
FRX Polymers (1)
G202 (1)
GE (1)
General (2)
General Cannabis (1)
generic drugs (1)
GenSpera (2)
Geomega (1)
Geomega Resources (1)
GNSZ (2)
graphite (1)
green infrastructure (3)
Gunnar Weikert (1)
HelioVolt Corp (1)
HON (2)
Hüper Optik (1)
HXL (1)
Hycrete (1)
immunotherapy (1)
Industry Research (4)
infrared touchscreen (1)
Inscrybe (1)
InVivo Therapeutics (7)
James Hayward (1)
JCI (2)
Jeff Kraws (3)
junior mining (1)
KIACTA (1)
law enforcement technology (1)
Lemnis Lighting (1)
Leslie Ziegler (1)
Long Island North Shore (1)
Long range acoustic devices (3)
LRAD (3)
LRAD Corp. (3)
Mario Spino (1)
Mark Reddish (2)
MedPro (2)
MiaSolé (2)
mineral exploration (1)
MMFX Technologies (1)
MPSP (2)
Multikine (2)
nanotechnology (4)
NEON.OB (1)
Neonode Inc. (1)
NEOVA (1)
Neuralstem (3)
New Research (19)
New York Senate Higher Education Committee (1)
Newsworthy Events (15)
niobium (1)
no!no! (1)
Novo Nordisk (1)
NVIV (6)
OneMedForum (1)
OneMedPlace (1)
Opower (1)
paralysis (1)
Peregrine (1)
Pharmascience (1)
PHMD (3)
PhotoMedex Inc. (3)
plant DNA (1)
Pluristem Therapeutics (2)
PPHM (1)
Prefilled Syringe (1)
Puget Sound Blood Center (1)
PURETi (1)
R3 (1)
Radiancy (2)
Randy Milby (1)
Rare earth elements (1)
REE (1)
SAT (1)
SearchCore (1)
Sebastien Vezina (1)
Serious Energy (1)
SHLM (1)
SHW (1)
SI (1)
Silver Spring Networks (1)
Soladigm (1)
spinal injury (2)
stocks (4)
SYN (1)
Synthetic Biologics (1)
T3 Motion (2)
T3 Series (2)
TAP Vaccine (1)
TapImmune (2)
Targeted Cancer Therapies (1)
Targeted Therapies (1)
Targeted Therapy (1)
telecare (1)
telemedicine (1)
Tendril Networks (1)
The NanoSteel Company (1)
Timet (1)
touch technology (1)
TPIV (1)
TTTM (2)
Unilife Corp. (2)
UNIS (1)
University of Albany (1)
VIVIMIND (1)
wordlogic predictive keyboard (2)
XTRAC (1)
zForce (1)
Current Articles
|
RSS Feed
LRAD Corp.'s Acoustic Technology To Be Used at 2012 NATO Summit
BELLUS Health Reports 1Q Financial Results, Provides Corporate Update
LRAD Corp. Receives $1.7 Million LRAD-RX Order for Asian Maritime Security
InVivo Therapeutics (NVIV) Reports First Quarter 2012 Financial Results, Provides Business Update
Sustainable Technologies Gain Momentum: New Report Highlights News
InVivo Therapeutics (NVIV) Adds Senior Leadership in Preparation for Human Clinical Trial
Crystal Research CEO Jeffrey Kraws Appointed Chairman of the Board, Synthetic Biologics (SYN-NYSE Amex)
PhotoMedex (PHMD) 1Q 2012 Revenues Increased 45% Year Over Year
MedPro and Unilife Featured in Drug Development & Delivery Magazine
Israeli Government Awards T3 Motion 2-Year Electric Vehicle Contract
Management Appointments at CorMedix, TapImmune, and Geomega Resources
QUARTERLY UPDATE: InVivo Therapeutics (NVIV) Poised for Growth
Investor Highlights for PhotoMedex, Inc. (PHMD) (Week of 4/23-4/27)
NEW REPORT on Document Capture Technologies (DCMT)
Jeff Kraws Weighs In on Supreme Court Victory for Generic Drug Makers
UPDATE: NVIV (InVivo Therapeutics) up 13% on positive news from FDA
New treatment for spine injuries could reverse paralysis: InVivo poised to enter clinical trials
NEW REPORT: Recent Developments in Nanotechnology You Need to Know
Unilife Corp. (UNIS): There's a new app for that
NEW REPORT on PhotoMedex (PHMD): Marketer of no!no! Hair and more
Neonode (NEON-OTC.BB) is Changing Your Touchscreen
APDN's Revenues Rise 63% in the First Quarter FY 2012
Authentidate Holding Corp. (ADAT) Second Quarter FY 2012 Update
Independent Equity Research Report on T3 Motion, Inc. (TTTM)
Independent Equity Research Report on LRAD Corp. (LRAD-NASDAQ)
APDN's Technology Could Prevent Cheating on Standardized Tests
TapImmune's New State-of-the-Art Lab Facilities and Office Space
InVivo Therapeutics' Frank Reynolds Interviewed on FOX40
APDN Uses Nanotechnology to Prevent Counterfeit Computer Chips
Healthcare Conferences and News: Week of 1/9 to 1/13
Corporate Milestone Update for GenSpera (GNSZ)
Exploring Rare Earth Elements to Meet Worldwide Demand
Nanotechnology & the Built Environment
APDN’s Anti-Counterfeiting Technology Addresses New Federal Legislation
New Research Available on InVivo Therapeutics Holdings Corp. (NVIV-OTC)
CEL-SCI Continues Advancing to the Start of Phase III Trials for Multikine
Advances in Alzheimer’s Research Fuels the Development of Possible Treatments
New Research Available on Adamis Pharmaceuticals Corp. (ADMP-OTC)
Quarterly Update Available on Document Capture Technologies (DCMT-OTC)
First Quarter 2011 Financial Summary and Business Update Published on BELLUS Health
New Research Available on MedeFile International Inc. (MDFI-OTC)
University of Texas Selects WordLogic Text Entry System for Texas Technology Access Program
Quarterly Update Issued on GenSpera, Inc.
Dell Inc. Signs Reseller Agreement with WordLogic Corp. and other news
Quarterly Update Issued on Applied DNA Sciences, Inc.
New Research Issued on General Cannabis, Inc. (CANA-OTC)
New Research Available: Document Capture Technologies, Inc.
New research available on WordLogic Corp. (WLGC-OTC)
M&A activity on the rise for 2011
New research available on Bioniche Life Sciences
Recent Financial Results and Updates
Large Pharma Increasing Investment in Emerging Countries
Unilife to report 2Q FY 2011 financial results in the U.S. on Feb. 14
Updated business outlook available on Peregrine Pharmaceuticals
New Research Issued on Laep Investments Ltd.
Out with the old and in with the new…
A Solid Start to 2011
Both Sides of the Fence for 2011
New Research Released on BELLUS Health Inc.
Mid-Week News Highlights (12/6-12/8) from CRA’s Coverage Universe
Updated Executive Informational Overview Released on Authentidate Holding Corp.
Unilife Reports Financial Results and Significant Milestones
New Research Available on CorMedix Inc.
Up to $1 Billion in New Credits/Grants for Healthcare
Recent Financial Results and Corporate Updates
New research available on Applied DNA Sciences
Bioniche Named Among Top Employers in Canada
New research available at www.crystalra.com
Promising Clinical Events from Neuralstem and Peregrine
Corporate Update from TapImmune and Positive Phase II Data from ACT Biotech
CEL-SCI’s progress toward the start of its Phase III trial
News from Generex, Pluristem, and Vena
Your unbiased source for under-the-radar investing ideas.
Error sending email
Email sent successfully
Email article
Email To :
Email From :
Message :